Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 16/20 | 0.72 |
| ▸ | MARK3 | P27448 | 3/20 | 0.54 |
| ▸ | GSK3B | P49841 | 3/20 | 0.54 |
| ▸ | CAMK2B | Q13554 | 3/20 | 0.54 |
| ▸ | MARK2 | Q7KZI7 | 3/20 | 0.54 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.54 |
| ▸ | SRPK1 | Q96SB4 | 3/20 | 0.54 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.54 |
| ▸ | CDC7 | O00311 | 2/20 | 0.54 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.54 |
| ▸ | NEK4 | P51957 | 2/20 | 0.54 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.54 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.54 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.54 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.54 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.54 |
| ▸ | EEF2K | O00418 | 1/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | PAK4 | O96013 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205888 | 0.91 | MCL1 (0.78) | MCL1MARK3GSK3BCAMK2BMARK2 | |
| SCHEMBL17044268 | 0.87 | MCL1 (0.55) | MCL1MARK3GSK3BCAMK2BMARK2 | |
| SCHEMBL4164209 | 0.87 | MCL1 (0.65) | MCL1MARK3GSK3BCAMK2BMARK2 | |
| SCHEMBL2204548 | 0.87 | MCL1 (0.85) | MCL1MARK3GSK3BCAMK2BMARK2 | |
| SCHEMBL2201248 | 0.87 | MCL1 (0.88) | MCL1MARK3GSK3BCAMK2BMARK2 | |
| SCHEMBL15622465 | 0.84 | MCL1 (1.00) | MCL1MARK3GSK3BCAMK2BMARK2 | |
| SCHEMBL2202582 | 0.83 | MCL1 (0.75) | MCL1MARK3GSK3BCAMK2BMARK2 | |
| SCHEMBL2204955 | 0.81 | MCL1 (0.85) | MCL1MARK3GSK3BCAMK2BMARK2 | |
| SCHEMBL2203601 | 0.81 | MCL1 (0.88) | MCL1MARK3GSK3BCAMK2BMARK2 | |
| SCHEMBL2204297 | 0.81 | MCL1 (0.88) | MCL1MARK3GSK3BCAMK2BMARK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134685-B1 | 7-NONSUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2015-09-02 | — | — | EP | claimed |
| US-20110263599-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES | 2011-10-27 | — | — | US | claimed |
| EP-2134685-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | claimed |
| US-20090124616-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | claimed |
| WO-2008130970-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | claimed |
| EP-2134685-B1 | 7-NONSUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8853209-B2 | 1-oxyalkyl-2-carboxy-7-nonsubstituted indole derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20110263599-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES | 2011-10-27 | — | — | US | disclosed |
| US-7981888-B2 | 1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives | ABBOTT LABORATORIES (US) | 2011-07-19 | — | — | US | disclosed |
| EP-2134685-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090124616-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2008130970-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124616-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MCL1 1/4885MARK3 2407/4885GSK3B 938/4885 |
| US-20110263599-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MCL1 1/4885MARK3 2407/4885GSK3B 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.